title: Pharmacological activation of PPARbeta promotes rapid and calcineurin-dependent fiber remodeling and angiogenesis in mouse skeletal muscle.
abstract: Recent studies have shown that administration of peroxisome proliferator-activated receptor-beta (PPARbeta) agonists enhances fatty acid oxidation in rodent and human skeletal muscle and that muscle-restricted PPARbeta overexpression affects muscle metabolic profile by increasing oxidative myofiber number, which raises the possibility that PPARbeta agonists alter muscle morphology in adult animals. This possibility was examined in this study in which adult mice were treated with a PPARbeta agonist, and the resulting changes in myofiber metabolic phenotype and angiogenesis were quantified in tibialis anterior muscles. The findings indicate a muscle remodeling that is completed within 2 days and is characterized by a 1.63-fold increase in oxidative fiber number and by a 1.55-fold increase in capillary number. These changes were associated with a quick and transient upregulation of myogenic and angiogenic markers. Both myogenic and angiogenic responses were dependent on the calcineurin pathway, as they were blunted by cyclosporine A administration. In conclusion, the data indicate that PPARbeta activation is associated with a calcineurin-dependent effect on muscle morphology that enhances the oxidative phenotype.
authors.affiliation: INSERM U907, Faculté de Médecine Université de Nice-Sophia Antipolis, 28 Avenue de Valombrose, Nice Cedex, France.
authors.forename: Céline
authors.initials: C
authors.lastname: Gaudel
authors.forename: Chantal
authors.initials: C
authors.lastname: Schwartz
authors.forename: Christian
authors.initials: C
authors.lastname: Giordano
authors.forename: Nada A
authors.initials: NA
authors.lastname: Abumrad
authors.forename: Paul A
authors.initials: PA
authors.lastname: Grimaldi
mesh_terms: D000818:Animals; D019703:Calcineurin / Q000502:physiology*; D065095:Calcineurin Inhibitors; D016572:Cyclosporine / Q000494:pharmacology; D007150:Immunohistochemistry; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D018485:Muscle Fibers, Skeletal / Q000187:drug effects / Q000502:physiology; D018482:Muscle, Skeletal / Q000098:blood supply / Q000187:drug effects / Q000502:physiology*; D017570:MyoD Protein / Q000502:physiology; D051787:Myogenic Regulatory Factor 5 / Q000502:physiology; D018919:Neovascularization, Physiologic / Q000187:drug effects / Q000502:physiology; D048068:PPAR-beta / Q000819:agonists*; D010805:Physical Conditioning, Animal / Q000502:physiology*; D013385:Succinate Dehydrogenase / Q000378:metabolism; D013844:Thiazoles / Q000494:pharmacology*; D010636:Phenols; D013438:Sulfhydryl Compounds
chemical_list: D019703:Calcineurin; D065095:Calcineurin Inhibitors; D016572:Cyclosporine; D017570:MyoD Protein; D051787:Myogenic Regulatory Factor 5; D048068:PPAR-beta; D013385:Succinate Dehydrogenase; D013844:Thiazoles; C497418:Myf5 protein, mouse; C057363:MyoD1 myogenic differentiation protein; C479979:(4-(((2-(3-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-1,3-thiazol-5-yl)methyl)sulfanyl)-2-methylphenoxy)acetic acid; D010636:Phenols; D013438:Sulfhydryl Compounds